ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
3
views
0
references
Top references
cited by
2
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,265
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL
Author(s):
Albain
Publication date:
2016
Journal:
Cancer Res
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Scientific Ocean Drilling Expedition Research Results
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
1,265
A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
Authors:
BJ Monk
,
A. Poveda
,
I Vergote
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Authors:
Ignace Vergote
,
Russell J Schilder
,
Charles Pippitt
…
Incidence and management of edema associated with trebananib (AMG 386)
Authors:
Bradley Monk
,
Sandrina Lambrechts
,
Lindsey E. Minion
…
See all similar
Cited by
2
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial
Authors:
W Symmans
,
Christina Yau
,
Yunn-Yi Chen
…
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Authors:
L DU
,
C. Yau
,
L. Brown-Swigart
…
See all cited by